The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only FDA-approved treatment shown to ...
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...
Sold as Susvimo, it's the first device that slowly releases ranibizumab, a medicine that treats eye diseases, so patients don’t need frequent injections. DME affects about 750,000 people in the ...
The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback